Safety, Tolerability, and Who Benefits Most From Personalized Dosing Adjustment Higher semaglutide doses are not universally better
Despite extensive animal data suggesting efficacy across depression, anxiety, cognitive decline, and ADHD-relevant models, not a single human clinical trial exists for any mental health application
In Trial 7, cholecystitis was reported in 1.1% treated with semaglutide tablets 14 mg and in 0.7% of placebo-treated patients
This approach minimizes any potential side effects while still initiating the healing cascade
Potential for Other Conditions Beyond EPP, researchers have explored the use of afamelanotide and other melanocortin agonists for conditions such as vitiligo, a disorder characterised by loss of skin pigmentation, and polymorphous light eruption (PLE), a form of sun allergy
This is much higher than the 2.1 rate for bupropion-naltrexone users and 1.1 for sleeve gastrectomy patients [4]